Analysis links DPP-4 inhibitors to reduced CVD risk in diabetes

09/25/2011 | InternalMedicineNews.com (free registration)

A meta-analysis presented at the European Association for the Study of Diabetes showed that type 2 diabetes patients who took dipeptidyl peptidase–4 inhibitors had a 31% decreased risk of major cardiovascular events, compared with those taking a placebo or other treatments. However, the review has limitations, including that cardiovascular events were not the end point in any of the studies, and further investigation is needed, the lead researcher said.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ